Addressing Ways to Improve Supply-Chain Security: A Perspective from Pfizer - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Addressing Ways to Improve Supply-Chain Security: A Perspective from Pfizer
A Q&A with Brian Johnson, senior director of supply chain security at Pfizer, moderated by Patricia Van Arnum. Part of a special Ingredients issue.

Pharmaceutical Technology
Volume 35, pp. s39-s40

Drug-authentication strategies

PharmTech: Counterfeit goods are a concern not only in terms of revenue loss, but also in the misdirection of consumers believing they are taking a drug that may or may not be effective or even potentially harmful. What types of technologies and strategies can a pharmaceutical company use to authenticate its drug product to the consumer?

Johnson: Pfizer has a broad range of technologies that it uses to authenticate drug products with the consumer, such as color-shifting inks, radio frequency identification, and 2D barcodes. These examples are primarily overt technologies, meaning they are typically adapted to the end user that will be performing the authentication. Track-and-trace initiatives around the world are driving the need for standardization of technologies, and the use of 2D barcodes for authentication is becoming the technology of choice.

Pfizer's perspective

PharmTech: Are there specific approaches in place at Pfizer that you would like to discuss in terms of drug-product authentication or other anticounterfeiting approaches? Can you provide best practices or examples of specific programs in place at Pfizer to achieve supply-chain security?

Johnson: Pfizer typically has used a risk-based approach for determining the authentication needs for our drug products. In other words, we address the need for anticounterfeiting and authentication measures on an individual product basis and based on the market/regions where the product is sold. We are implementing a life-cycle approach to help us formalize the process for choosing when and what to use and also when to discontinue use over the life cycle of the products.

I think the key to Pfizer's approach to supply-chain security was the development of a "One Pfizer" strategy across the company. We recognized that the threats were increasing, our business was rapidly changing, and we could improve our collaboration/alignment across the different functional groups involved in protecting our supply chains. We defined the supply chain as starting with raw materials that we use in our products until the finished product is delivered to our patients. We are focusing on strengthening processes across the supply chain.

To provide leadership and governance, we created a supply-chain security function and a standing cross-functional team. Some of the functional groups represented on this team include quality, global security, procurement, commercial trade, global logistics and supply, external supply, packaging technology, and public affairs.

Read more from Johnson about supply chain security


1. FDA, "Pathway to Global Product Safety and Quality" Report (Rockville, MD, July 7, 2011).

2. EC Directive 2011/62/EU, Directive on Falsified Medicinal Products (Brussels, June 2011).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here